AVEO Pharmaceuticals Inc.

6.29-0.0200-0.32%Vol 668.47K1Y Perf 63.38%
Apr 13th, 2021 14:47 DELAYED
BID6.29 ASK6.30
Open6.27 Previous Close6.31
Pre-Market6.25 After-Market-
 -0.06 -0.95%  - -
Target Price
22.75 
Analyst Rating
Strong Buy 1.00
Potential %
261.11 
Finscreener Ranking
★★★+     52.53
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★+     43.22
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★★     52.12
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap170.65M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
18.37 
Earnings Date
29th Apr 2021

Today's Price Range

6.176.47

52W Range

3.6018.24

5 Year PE Ratio Range

-20.30-4.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-10.88%
1 Month
-49.28%
3 Months
-21.32%
6 Months
-0.79%
1 Year
63.38%
3 Years
-77.30%
5 Years
-34.95%
10 Years
-95.37%

TickerPriceChg.Chg.%
AVEO6.29-0.0200-0.32
AAPL134.483.24002.47
GOOG2 267.0012.21000.54
MSFT258.142.23000.87
XOM55.650.15000.27
WFC39.85-0.9200-2.26
JNJ159.18-2.4600-1.52
FB311.990.45000.14
GE13.47-0.1200-0.88
JPM154.62-1.3300-0.85
Financial StrengthValueIndustryS&P 500US Markets
3.70
3.90
0.27
0.41
-21.20
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
-
-564.50
-564.20
-515.80
-13.53
RevenueValueIndustryS&P 500US Markets
5.24M
0.15
17.88
2.75
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.38-0.44-15.79
Q03 2020-0.24-0.33-37.50
Q02 2020-0.51-0.4217.65
Q01 2020-0.50-0.52-4.00
Q04 2019-0.58-0.2851.72
Q03 20190.101.00900.00
Q02 2019-0.60-0.2066.67
Q01 2019-0.50-0.60-20.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.5511.29Positive
6/2021 QR-0.4624.59Positive
12/2021 FY-1.557.19Positive
12/2022 FY-0.1087.80Positive
Next Report Date29th Apr 2021
Estimated EPS Next Report-0.55
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume668.47K
Shares Outstanding27.13M
Trades Count4.31K
Dollar Volume2.74M
Avg. Volume2.36M
Avg. Weekly Volume1.03M
Avg. Monthly Volume1.79M
Avg. Quarterly Volume2.59M

AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) stock closed at 6.31 per share at the end of the most recent trading day (a -7.48% change compared to the prior day closing price) with a volume of 1.44M shares and market capitalization of 170.65M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. AVEO Pharmaceuticals Inc. CEO is Michael P. Bailey.

The one-year performance of AVEO Pharmaceuticals Inc. stock is 63.38%, while year-to-date (YTD) performance is 9.36%. AVEO stock has a five-year performance of -34.95%. Its 52-week range is between 3.6 and 18.24, which gives AVEO stock a 52-week price range ratio of 18.37%

AVEO Pharmaceuticals Inc. currently has a PE ratio of -4.10, a price-to-book (PB) ratio of 6.82, a price-to-sale (PS) ratio of 41.42, a price to cashflow ratio of 19.50, a PEG ratio of 2.32, a ROA of -58.33%, a ROC of -59.37% and a ROE of -138.30%. The company’s profit margin is -13.53%, its EBITDA margin is -564.20%, and its revenue ttm is $5.24 Million , which makes it $0.15 revenue per share.

Of the last four earnings reports from AVEO Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. AVEO Pharmaceuticals Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for AVEO Pharmaceuticals Inc. is Strong Buy (1), with a target price of $22.75, which is +261.11% compared to the current price. The earnings rating for AVEO Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AVEO Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AVEO Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.85, ATR14 : 0.61, CCI20 : -82.96, Chaikin Money Flow : -0.34, MACD : -0.14, Money Flow Index : 16.93, ROC : -21.13, RSI : 39.03, STOCH (14,3) : 1.71, STOCH RSI : 0.00, UO : 32.67, Williams %R : -98.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AVEO Pharmaceuticals Inc. in the last 12-months were: Anthony A. Florence (Buy at a value of $7 499 998), Forest Baskett (Buy at a value of $7 499 998), Joshua Makower (Buy at a value of $7 499 998), Peter Sonsini (Buy at a value of $7 499 998), Sandell D Scott (Buy at a value of $7 499 998)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company's aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.

CEO: Michael P. Bailey

Telephone: +1 617 588-1960

Address: One Broadway, Cambridge 02142, MA, US

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

65%35%

News

Stocktwits